Evelo Biosciences, Inc. (EVLO)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2022 | 48.87 Million USD | -10.05% |
| 2021 | 54.34 Million USD | 35.73% |
| 2020 | 40.03 Million USD | 103.92% |
| 2019 | 19.63 Million USD | 59.56% |
| 2018 | 12.3 Million USD | 23.47% |
| 2017 | 9.96 Million USD | 0.35% |
| 2016 | 9.93 Million USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 Q2 | 3.87 Million USD | -15.35% |
| 2023 Q1 | 4.57 Million USD | -90.63% |
| 2023 Q3 | - USD | -100.0% |
| 2022 Q3 | 42.58 Million USD | -9.99% |
| 2022 Q2 | 47.31 Million USD | -8.94% |
| 2022 Q1 | 51.95 Million USD | -4.39% |
| 2022 FY | 48.87 Million USD | -10.05% |
| 2022 Q4 | 48.87 Million USD | 14.78% |
| 2021 Q4 | 54.34 Million USD | -1.0% |
| 2021 Q1 | 38.72 Million USD | -3.29% |
| 2021 Q2 | 55.4 Million USD | 43.09% |
| 2021 FY | 54.34 Million USD | 35.73% |
| 2021 Q3 | 54.89 Million USD | -0.93% |
| 2020 Q4 | 40.03 Million USD | -0.96% |
| 2020 Q2 | 30.78 Million USD | -1.23% |
| 2020 FY | 40.03 Million USD | 103.92% |
| 2020 Q1 | 31.17 Million USD | 58.76% |
| 2020 Q3 | 40.42 Million USD | 31.31% |
| 2019 Q2 | 14.85 Million USD | 42.05% |
| 2019 FY | 19.63 Million USD | 59.56% |
| 2019 Q4 | 19.63 Million USD | 0.43% |
| 2019 Q3 | 19.54 Million USD | 31.59% |
| 2019 Q1 | 10.45 Million USD | -15.01% |
| 2018 Q3 | 14.15 Million USD | -4.05% |
| 2018 FY | 12.3 Million USD | 23.47% |
| 2018 Q4 | 12.3 Million USD | -13.07% |
| 2018 Q2 | 14.75 Million USD | 0.23% |
| 2018 Q1 | 14.71 Million USD | 47.69% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q4 | 9.96 Million USD | 0.0% |
| 2017 FY | 9.96 Million USD | 0.35% |
| 2016 FY | 9.93 Million USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| America Great Health | 1.12 Million USD | -4252.003% |
| Ampio Pharmaceuticals, Inc. | - USD | -Infinity% |
| Aridis Pharmaceuticals, Inc. | 1.29 Million USD | -3683.204% |
| Biora Therapeutics, Inc. | 43.73 Million USD | -11.759% |
| Bio-Path Holdings, Inc. | 10 Thousand USD | -488690.0% |
| Better Therapeutics, Inc. | 10.34 Million USD | -372.352% |
| Calithera Biosciences, Inc. | 136 Thousand USD | -35840.441% |
| Comera Life Sciences Holdings, Inc. | 120.3 Thousand USD | -40530.247% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | - USD | -Infinity% |
| Eloxx Pharmaceuticals, Inc. | 8.69 Million USD | -462.345% |
| Evolutionary Genomics, Inc. | 3.74 Million USD | -1205.617% |
| Finch Therapeutics Group, Inc. | 28.4 Million USD | -72.091% |
| Galera Therapeutics, Inc. | 151.04 Million USD | 67.64% |
| Innovation1 Biotech Inc. | 218.99 Thousand USD | -22219.28% |
| Kiromic BioPharma, Inc. | 911.5 Thousand USD | -5262.479% |
| Molecular Templates, Inc. | 9.74 Million USD | -401.735% |
| Navidea Biopharmaceuticals, Inc. | 1.87 Million USD | -2511.455% |
| NexImmune, Inc. | - USD | -Infinity% |
| Orgenesis Inc. | 19.06 Million USD | -156.354% |
| Panbela Therapeutics, Inc. | 4.19 Million USD | -1065.451% |
| Point of Care Nano-Technology, Inc. | - USD | -Infinity% |
| PaxMedica, Inc. Common Stock | - USD | -Infinity% |
| Scopus BioPharma Inc. | - USD | -Infinity% |
| Sorrento Therapeutics, Inc. | 104.33 Million USD | 53.153% |
| Statera Biopharma, Inc. | 11.43 Million USD | -327.595% |
| TRACON Pharmaceuticals, Inc. | 732 Thousand USD | -6577.459% |
| Trevena, Inc. | 35.23 Million USD | -38.731% |
| Vaxxinity, Inc. | 13.26 Million USD | -268.564% |
| Vaccinex, Inc. | 26 Thousand USD | -187896.154% |
| Vicapsys Life Sciences, Inc. | - USD | -Infinity% |
| Viracta Therapeutics, Inc. | - USD | -Infinity% |
| ZIVO Bioscience, Inc. | - USD | -Infinity% |